Jose M. Arguinano
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 18, 2023
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
Journal: Leukemia & lymphoma
Published: September 20, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 14, 2022
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 05, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Journal: Blood cancer journal
Published: January 18, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Journal: Clinical lymphoma, myeloma & leukemia
Published: December 30, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026